# A Drug Kept Pancreatic Cancer Patients Alive Twice as Long. For the First Time, It Covers the Majority of Tumors. - Date: 2026-04-16 - Category: Biotech & Life Sciences Daraxonrasib extended median survival to 13.2 months versus 6.7 months for chemo, cutting death risk by 60 percent in a Phase III pancreatic cancer trial. More than 90 percent of pancreatic tumors carry the mutation it targets. ---